Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ELRIG Announces Drug Discovery 2013 Preliminary Programme and Call for Posters

Published: Thursday, May 02, 2013
Last Updated: Thursday, May 02, 2013
Bookmark and Share
The 7th Annual Drug Discovery Conference is anticipated to attract over 1000 delegates, engaging scientists involved in early stage drug discovery.

The 2013 programme will contain scientific presentations, an exhibition area with over 100 vendor booths, a networking event, poster sessions, Innovation Zone, Media Area and Careers Zone. Registration for the event is free, and delegates can register online at www.elrig.org.

The scientific sessions will feature presentations from leading scientists, including the show keynote address from Dr Ruth McKernan, CSO of Pfizer’s Neusentis Unit, on ‘Practical applications of stem cell-derived cells within drug discovery’. The eight scientific sessions are:

• Target & Biomarker Identification & Validation
• Advanced Cell Technologies
In vitro DMPK & Safety Screening
• Macromolecules as Therapeutics
• Innovations in Assay Development & Screening
• Science Led sample Management – putting the horse before the cart
• Oncology Drug Targets – where next?
• Macromolecules as Tools for Discovery & Target Validation

ELRIG is calling for poster abstract submissions, which should be sent to posters@elrig.org. This year a subset of poster abstracts will be selected for 10 minute oral presentations, to be given within the main symposia sessions. Delegates will be given the chance to vote for the best poster, with a prize for the poster receiving the highest number of votes.

In collaboration with SLAS (Society for Laboratory Automation and Screening), students, graduates and post-docs are again invited to submit a poster for entry into the Young Scientist Award, the winner of which will receive a $500 cash prize, as well as an expenses-paid trip to present and participate in the Student Poster Competition at SLAS2014, 18-22 January 2014 in San Diego, CA.

Following on from the success of last year’s Dragons Den,this will also be a feature of the 2013 event.  Companies are encouraged to come forward to pitch to the panel of ‘Dragons’.  To find out more please contact Adrian Kinkaid: adrian.kinkaid@elrig.org.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
'Poison Pill' Fed to Deadly Virus
Researchers have created a genetic modification within a virus (with funny name), rendering it unable to replicate, mutate or cause illness.
World First Alzheimer's Vaccine Breakthrough
Researchers have made a breakthrough discovery towards an effective vaccine for Alzheimer's by targeting associated proteins.
Immunotherapy Drug Combo Targets Cancer
Mayo Clinic researchers identify potential immunotherapy drug combination that shows therapeutic effects against advanced and metastatic cancers.
Study Shows Sandoz Biosimilar Equivalent to Originator Drug
New data shows Sandoz biosimilar candidate has equivalent efficacy to originator etanercept following comparison in psoriasis.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Immunotherapy Reduces Rheumatoid-Linked Cardiovascular Risk
Study shows combination of two extra-low dose anticytokines reduces disease activity and cardiovascular events.
Viable HIV Vaccine Confirmed by Study
HIV Study in macaques confirms clinically viable vaccine opening the way for future treatment in humans.
Sanofi Working on Zika Vaccine with U.S. Army
Sanofi is working in conjunction with the U.S. Army to develop possible Zika vaccine at faster rate following research agreement.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!